AUTL - Company ID 0001730463
The table below shows Autolus Therapeutics plc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$283.57M | -$206.27M | -$145.59M | -$112.31M | -$117.86M | -$117.76M |
| Capital expenditure | $19.04M | $22.07M | $10.99M | $10.84M | $8.86M | $14.68M |
| Investing cash flow | $158.46M | -$394.55M | -$10.99M | -$10.84M | -$8.86M | -$14.68M |
| Dividends paid | - | - | - | - |
Autolus Therapeutics plc reported operating cash flow of -$283.57M for fiscal year 2025. That is down 37.5% from -$206.27M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.85M (FY 2016) to -$283.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$4.34M | $589.55M | -$883.00K | $223.61M | $284.06M | $74.42M |